Key factors
symAMYT
exchUS
MCap942.76M
Beta0.765
PE Ratio39.72
EPS0.37
Div date0000-00-00
Yesterday
symAMYT
exchUS
close14.7
50 Day MA14.61
200 Day MA9.990
52 Week High14.76
52 Week Low14.54
Target Price 18.67
Market Cap Mln942.76
Share statistics
Shares Outstanding64.13M
Shares Float37.38M
Percent Institutions77.30
PercentInsiders0.078
SharesShort121.19K
Short Ratio0.58
Shares Short Prior Month77633
Short Percent1.539
Revenue TTM 243.62M
Revenue Per Share TTM 3.803
Quarterly Revenue Growth YOY 8.200
Gross Profit TTM 120.84M
EBITDA-73.8M
Diluted Eps TTM0.37
earning
Operating Margin TTM -0.16
Trailing PE 39.72
EPS Estimate Current Quarter -0.05
EPS Estimate Next Quarter -0.07
EPS Estimate Next Year -0.03
Earnings Share 0.37
Dividend
Dividend Date0000-00-00
Last Split Date 0000-00-00
business
Enterprise Value Ebitda 6.606
Enterprise Value Revenue2.396
Book Value /share 5.069
Price Book MRQ 1.400
Price Sales TTM 1.874
ProfitMargin -0.00
ReturnOnAssetsTTM -0.03
ReturnOnEquityTTM-0.00
Gic GroupPharmaceuticals, Biotechnology & Life Sciences
Gic IndustryPharmaceuticals
Gic Sector Health Care
Gic Sub Industry Pharmaceuticals
Industry Drug Manufacturers - Specialty & Generic
SectorHealthcare
ISIN US03217L1061
CIK 1783010
Code AMYT
CountryISO US
Currency CodeUSD
Currency Name US Dollar
Exchange NASDAQ
Currency Symbol $
Type Common Stock
UpdatedAt 2023-06-20
is Delisted 1
Delisted Date 2023-04-12
Home Category ADR
Fiscal Year End December
ForwardPE 67.56
Full Time Employees289.0
IPODate 2019-12-31
MostRecent Quarter2022-09-30
Contact
NameAmryt Pharma Holdings Ltd
Address45 Mespil Road, Dublin, Ireland, 4
Country NameUSA
Phone353 1 518 0200
Web URLhttps://www.amrytpharma.com
Logo URL/img/logos/US/AMYT.png
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.